Cytomegalovirus infection and disease after autologous CD34-selected peripheral blood stem cell transplantation for multiple myeloma: no evidence of increased incidence based on polymerase-chain-reaction monitoring.
作者信息
Peggs K S, Ings S J, Kottaridis P D, Yong K, Williams C D, Goldstone A H, Mackinon S
出版信息
Blood. 2000 Jul 1;96(1):369-70.
PMID:10939802
Abstract
摘要
相似文献
1
2
Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells in multiple myeloma: the issue of safety.
Exp Hematol. 2001 Jan;29(1):1-2. doi: 10.1016/s0301-472x(00)00664-0.
3
4
Cytomegalovirus infection in patients undergoing autologous peripheral blood stem cell transplantation.
Int J Infect Dis. 2002 Mar;6(1):83-4. doi: 10.1016/s1201-9712(02)90143-8.
5
Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality.
Blood. 2001 Apr 1;97(7):2183-5. doi: 10.1182/blood.v97.7.2183.
6
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation.
Blood. 1999 Dec 15;94(12):4029-35.
7
Cytomegalovirus colitis after autologous transplantation for multiple myeloma.
Br J Haematol. 2000 Sep;110(4):894-6. doi: 10.1046/j.1365-2141.2000.02282.x.
8
9
Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients.
PLoS One. 2018 Jul 23;13(7):e0200221. doi: 10.1371/journal.pone.0200221. eCollection 2018.
10
Cytomegalovirus infection following transplantation of autologous CD34-selected progenitor cells.
Blood. 2000 Aug 1;96(3):1194.
引用本文的文献
1
Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation.
Ann Hematol. 2024 Aug;103(8):2893-2904. doi: 10.1007/s00277-024-05641-y. Epub 2024 Mar 13.
2
Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
Int J Hematol. 2004 Jan;79(1):85-91. doi: 10.1007/BF02983539.
3
High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells.
Bone Marrow Transplant. 2001 Nov;28(9):849-57. doi: 10.1038/sj.bmt.1703244.
Zotero 插件